Racetam / AMPA receptor research
Aniracetam is a synthetic pyrrolidinone compound studied for its effects on glutamate signaling and cognition. Its research history spans receptor experiments, animal behavior, and older trials in people with cognitive impairment. These are different kinds of evidence: a measurable receptor effect does not establish improved memory in healthy people. The human trials highlighted here reached different conclusions, making study design and population central to interpretation.
Mixed human and preclinical evidenceA focused reference from the Disguised Alpha research network.
Disguised Alpha catalog
Open the exact product listing for its format and documentation. Published studies do not validate a supplier’s finished product.
01 / The science
A clear starting point for the mechanisms, experimental models and questions behind the compound.
Aniracetam potentiated AMPA-related responses in frog oocytes expressing rat brain receptors and in rat hippocampal slices. The work supports an allosteric mechanism: modifying a receptor response rather than simply replacing glutamate. Findings from isolated experimental systems cannot specify the size or reliability of an effect in a person.
Read the primary source ↗Structural and electrophysiology experiments place aniracetam at the interface between AMPA receptor subunits. Researchers linked this interaction to slower receptor deactivation. This offers a molecular explanation for a laboratory observation; it does not answer whether a particular commercial formulation changes everyday cognition.
Read the primary source ↗Older placebo-controlled trials enrolled people with Alzheimer-type dementia or probable Alzheimer disease. One reported no clinical advantage, while another reported differences favoring aniracetam. Their differing populations, durations, and outcomes should remain visible rather than being compressed into a claim that aniracetam reliably improves memory.
Read the primary source ↗02 / Read with context
The selected research applies to the tested molecule, experimental model and conditions. It does not establish equivalent effects for a commercial formulation or support assumptions about clinical benefit or long-term safety.
03 / Selected publications
Original records, study models and the limits that matter when interpreting a result.
The investigators identified a binding site for aniracetam in the GluR2 ligand-binding domain. Mutations affecting that site disrupted modulation, supporting a relationship between the observed structure and receptor behavior.
Reading limit: This is mechanistic evidence from experimental receptor systems. It does not measure clinical benefit or long-term safety.
Both groups improved on some cognitive tests, but the clinical assessment found no efficacy difference between aniracetam and placebo. Confusion led to discontinuation in four aniracetam recipients and one placebo recipient.
Reading limit: This small, older trial concerns dementia, not healthy-user enhancement. A separate 1991 trial of 109 patients reported a different result.
Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study ↗Researchers found no significant group differences across tests of learning, memory, motor behavior, anxiety-related behavior, and repetitive behavior. The negative findings are relevant when claims extend from impaired models to healthy subjects.
Reading limit: A mouse result cannot settle human efficacy. It does show why benefits should not be assumed across models.
A focused selection, not a systematic review. Studies concern the tested material and do not validate a supplier’s finished product.
Explore research & source notes →04 / Common questions
Quick answers for reading the science behind Aniracetam.
No. Its recorded structure is a small organic molecule containing a pyrrolidinone ring and a methoxybenzoyl group. Chemical identity and a product’s format are separate questions.
No. Receptor modulation establishes activity in the tested preparation. A claim about memory requires appropriately controlled behavioral or clinical evidence in the population being discussed.
Yes. The cited clinical trials studied cognitive impairment and dementia, with mixed results. They should not be presented as demonstrations of improved cognition in healthy adults.
Look at the enrolled population, comparator, duration, outcome measures, withdrawals, and tested formulation. A positive finding in one setting does not erase a negative study in another.
Continue your research
Explore the complete Aniracetam profile and related compounds in the Disguised Peptides research hub.
